Lowered A1C of 1.7%2.0% across doses Weight loss of 16.8% in the highest dose over 40 weeks without evidence of weight loss plateau The longer duration 80-week TRIUMPH-2 will more effectively evaluate the weight loss potential of retatrutide in those with type 2 diabetes and obesity, expected to result later this year Press release: To view or add a comment, sign in More Relevant Posts The FDA has approved Wegovy HD (semaglutide 7.2 mg) for adults with obesity
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022) FDA DailyMed (current GLP-1 prescribing information) MeAgain App Store listing MeAgain medication-level context tracker (GLP-1 Plotter) What MeAgain users say about dose tracking What Our Users Say I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication
Over time, while GLP-1 injections curbs our appetite and enhances feelings of fullness, this can lead to a reduction in food intake and ultimately contribute to weight loss
Retatrutide is currently an investigational medication undergoing clinical trials, and regulatory approval status may vary by country
The native version does critical metabolic work, stimulating insulin, quieting glucagon, slowing digestion
